PMID- 22539584
OWN - NLM
STAT- MEDLINE
DCOM- 20120926
LR  - 20131121
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 97
IP  - 7
DP  - 2012 Jul
TI  - Dynamic change of serum FGF21 levels in response to glucose challenge in human.
PG  - E1224-8
LID - 10.1210/jc.2012-1132 [doi]
AB  - AIMS: Fibroblast growth factor 21 (FGF21), an endocrine factor predominantly 
      secreted from liver, possesses multiple beneficial effect on energy metabolism 
      and insulin sensitivity in animals. This study aimed to investigate the acute 
      change of serum FGF21 in response to glucose challenge in humans. METHODS: A 75-g 
      oral glucose tolerance test was performed among 20 healthy subjects, 18 with 
      impaired glucose tolerance (IGT) and 21 with type 2 diabetes mellitus (T2DM). 
      Blood samples were collected for measurement of FGF21 and other biochemical 
      parameters. The associations of FGF21 with insulin and other metabolic parameters 
      were analyzed. RESULTS: Fasting serum FGF21 levels increased progressively from 
      healthy, IGT to T2DM subjects (P < 0.05 for global trend). After oral glucose 
      administration, the serum FGF21 level showed a similar biphasic change in all 
      three groups. It declined to a nadir level at 60 min and then increased gradually 
      to its peak level at 180 min. FGF21 levels at different time points of oral 
      glucose tolerance test negatively correlated with glucose levels in all subjects, 
      and the fold change of serum FGF21 at different time points (compared with the 
      basal level) were inversely associated with fold changes of insulin (P = 0.012) 
      and C-peptide (P = 0.043) levels in healthy subjects but not in IGT and T2DM 
      patients. CONCLUSIONS: The dynamic change of circulating FGF21 was associated 
      with alterations in insulin levels in response to glucose challenge in humans. 
      These findings support the role of FGF21 as a potential regulator of insulin 
      secretion and glucose metabolism in humans.
FAU - Lin, Zhuofeng
AU  - Lin Z
AD  - Metabolism Disease Research Center, the 2nd Affiliated Hospital, Wenzhou Medical 
      College, Zhejiang 325035, China.
FAU - Gong, Qi
AU  - Gong Q
FAU - Wu, Chaoming
AU  - Wu C
FAU - Yu, Jiawen
AU  - Yu J
FAU - Lu, Tingting
AU  - Lu T
FAU - Pan, Xuebo
AU  - Pan X
FAU - Lin, Shaoqiang
AU  - Lin S
FAU - Li, Xiaokun
AU  - Li X
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120426
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Insulin)
RN  - 0 (fibroblast growth factor 21)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - C-Peptide/blood/metabolism
MH  - Diabetes Mellitus, Type 2/blood/metabolism
MH  - Female
MH  - Fibroblast Growth Factors/*blood/metabolism/physiology
MH  - Glucose/administration & dosage/*pharmacology
MH  - Glucose Intolerance/blood/metabolism
MH  - Glucose Tolerance Test
MH  - Health
MH  - Humans
MH  - Insulin/blood/metabolism
MH  - Insulin Resistance/physiology
MH  - Male
MH  - Matched-Pair Analysis
EDAT- 2012/04/28 06:00
MHDA- 2012/09/27 06:00
CRDT- 2012/04/28 06:00
PHST- 2012/04/28 06:00 [entrez]
PHST- 2012/04/28 06:00 [pubmed]
PHST- 2012/09/27 06:00 [medline]
AID - jc.2012-1132 [pii]
AID - 10.1210/jc.2012-1132 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2012 Jul;97(7):E1224-8. doi: 10.1210/jc.2012-1132. Epub 
      2012 Apr 26.